Research


Financing Translation: Analysis of the NCATS Rare-Diseases Portfolio

with David E. Fagnan, N. Nora Yang, John C. McKew, Science Translational Medicine 7(2015), 276ps3.

View abstract

Financing Drug Discovery for Orphan Diseases

with David E. Fagnan, Austin A. Gromatzky, Jose-Maria Fernandez, Roger M. Stein, Drug Discovery Today 19 (2014), 533-538

View abstract

Return Smoothing, Liquidity Costs, and Investor Flows: Evidence from a Separate Account Platform

with Charles Cao, Grant Farnsworthy, Bing Liang

View abstract

Wall Street’s Next Bet: Cures for Rare Diseases

Fortune

View abstract

New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.

with Sourya V. Naraharisetti, Journal of Investment Management

View abstract

Financial Orphan Therapies Looking For Adoption

with Vikas Sukhatme, Kathy Fang, Vidula Sukhatme, Health Affairs Blog

View abstract

Open-Source Software for “Financing Drug Discovery for Orphan Diseases”

with David E. Fagnan, Austin A. Gromatzky, Jose-Maria Fernandez, Roger M. Stein

View abstract

Unintended Consequences of Expensive Cancer Therapeutics— The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

with Tito Fojo, Sham Mailankody, JAMA Otolaryngology-Head & Neck Surgery (2014)

View abstract

The Origin of Risk Aversion

with Ruixun Zhang, Thomas J. Brennan, Proceedings of the National Academy of Sciences 111(2014), 17777–17782.

View abstract

Dynamic Loss Probabilities and Implications for Financial Regulation

with Thomas J. Brennan, Yale Journal on Regulation 31(2014), 667–694.

View abstract

Follow me on © 2017 Andrew W. Lo, MIT Sloan School of Management. All rights reserved.
Design by: Opus Design